US · CHRS · BIOTECHNOLOGY
Coherus Oncology, Inc. (CHRS) intrinsic value and stock valuation
$0.37as of 2026-11-21 · Mkt cap 177.49M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Coherus Oncology, Inc. DCF and intrinsic value
InvestorsCraft values CHRS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CHRS’s statements →
Coherus Oncology, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $42.2M | $267M | $257.2M | $211M | $326.6M |
| Operating income | -$-179.53M | -$-111.67M | -$-203.2M | -$-256.88M | -$-263.86M |
| Net income | -$-170.29M | $28.5M | -$-237.89M | -$-291.75M | -$-287.1M |
| EPSd | -$-1.41M | $248.3K | -$-2.53M | -$-3.76M | -$-3.81M |
| Operating cash flow | -$-138.51M | -$-20.44M | -$-174.88M | -$-241.12M | -$-37.43M |
| Capital expenditure | $0.00 | $0.00 | -$-290K | -$-2.04M | -$-1.29M |
| Free cash flow | -$-138.51M | -$-20.44M | -$-175.17M | -$-243.16M | -$-38.72M |
| Total assets | $258.3M | $448.5M | $629.6M | $480.9M | $679.3M |
| Total debt | $40.3M | $269.9M | $480.8M | $480.4M | $419M |
| Net debt | -$-48.54M | $143.9M | $378M | $416.9M | $1.83M |
| Total equity | $61M | -$-131.99M | -$-193.43M | -$-137.42M | $97.7M |
| Cash and short-term investments | $172.1M | $126M | $117.8M | $191.7M | $417.2M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $42.2M | $267M | $257.2M | $211M | $326.6M |
| Cost of revenue | $17.7M | $117.6M | $159M | $70.1M | $57.6M |
| Gross profit | $24.4M | $149.4M | $98.3M | $141M | $269M |
| Research and development expenses | $105M | $93.3M | $109.4M | $199.4M | $363.1M |
| Selling, general and administrative expenses | $99M | $150.4M | $185.6M | $198.5M | $169.7M |
| Other expenses | $0.00 | $17.3M | $6.4M | $0.00 | $0.00 |
| Operating expenses | $204M | $261.1M | $301.5M | $397.8M | $532.8M |
| Cost and expenses | $221.7M | $378.6M | $460.4M | $467.9M | $590.4M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $9M | $27.2M | $40.5M | $32.5M | $23M |
| Depreciation and amortization | $3.92M | $5.28M | $3.79M | $3.7M | $3.45M |
| Ebitda | -$-170.2M | $60.9M | -$-193.94M | -$-255.58M | -$-260.69M |
| Operating income | -$-179.53M | -$-111.67M | -$-203.2M | -$-256.88M | -$-263.86M |
| Total other income/expenses, net | -$-3.59M | $140.2M | -$-35.07M | -$-34.87M | -$-23.24M |
| Income before tax | -$-183.12M | $28.5M | -$-238.27M | -$-291.75M | -$-287.1M |
| Income tax expense | $0.00 | $0.00 | -$-380K | $0.00 | $0.00 |
| Net income | -$-170.29M | $28.5M | -$-237.89M | -$-291.75M | -$-287.1M |
| Weighted average shares outstanding | $120.4M | $114.6M | $94.2M | $77.6M | $75.5M |
| Weighted average diluted shares outstanding | $120.4M | $114.8M | $94.2M | $77.6M | $75.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $172.1M | $126M | $117.8M | $191.7M | $417.2M |
| Net receivables | $18.4M | $122.3M | $260.5M | $110M | $123M |
| Inventory | $3.17M | $70.1M | $62.6M | $38.8M | $37.6M |
| Total current assets | $206.7M | $341.6M | $475.6M | $381.2M | $602.3M |
| Property, plant and equipment, net | $1.34M | $2.84M | $5.12M | $8.75M | $7.81M |
| Goodwill and intangible assets | $46.2M | $53.7M | $71.7M | $5.93M | $3.56M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $51.6M | $107M | $154M | $99.6M | $77M |
| Total assets | $258.3M | $448.5M | $629.6M | $480.9M | $679.3M |
| Accounts payable | $9.91M | $28.5M | $35.2M | $11.5M | $16.2M |
| Short-term debt | $1.83M | $1.69M | $2.15M | $4.32M | $3.49M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $141.9M | $283M | $331.8M | $138.7M | $165.3M |
| Long-term debt | $38.5M | $268.2M | $478.7M | $476.1M | $415.5M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $55.5M | $297.5M | $491.3M | $479.6M | $416.3M |
| Capital lease obligations | $3.29M | $4.98M | $7.47M | $9.36M | $10.7M |
| Total liabilities | $197.3M | $580.5M | $823M | $618.3M | $581.6M |
| Common stock | $10K | $10K | $10K | $10K | $10K |
| Retained earnings | -$-1.38B | -$-1.55B | -$-1.58B | -$-1.34B | -$-1.05B |
| Accumulated other comprehensive income (loss) | -$-200K | -$-280K | -$-250K | -$-250K | -$-270K |
| Total equity | $61M | -$-131.99M | -$-193.43M | -$-137.42M | $97.7M |
| Total investments | $83.3M | $0.00 | $14.9M | $128.1M | $0.00 |
| Total debt | $40.3M | $269.9M | $480.8M | $480.4M | $419M |
| Net debt | -$-48.54M | $143.9M | $378M | $416.9M | $1.83M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $168M | $28.5M | -$-237.89M | -$-291.75M | -$-287.1M |
| Depreciation and amortization | $3.92M | $5.28M | $3.79M | $3.7M | $3.45M |
| Stock-based compensation | $17M | $27.8M | $43.1M | $50.7M | $51.4M |
| Change in working capital | -$-5.84M | $55.9M | -$-36.83M | -$-79.26M | $42.4M |
| Accounts receivable | $93.6M | $149.4M | -$-150.68M | $13.1M | $34.1M |
| Inventory | -$-17.11M | -$-31.95M | -$-46.73M | -$-47.35M | -$-6.25M |
| Accounts payable | -$-19.56M | -$-3.94M | $23.8M | -$-4.55M | $870K |
| Net cash provided by operating activities | -$-138.51M | -$-20.44M | -$-174.88M | -$-241.12M | -$-37.43M |
| Investments in property, plant and equipment | $0.00 | $0.00 | -$-290K | -$-2.04M | -$-1.29M |
| Acquisitions, net | $0.00 | $0.00 | $840K | $0.00 | $1.29M |
| Net cash used for investing activities | $375.1M | $230.3M | $144.6M | -$-166.85M | -$-138.41M |
| Common stock issued | $8.25M | $1.46M | $74.2M | $6.36M | $40.9M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-273.7M | -$-186.97M | $69.6M | $54.3M | $51.9M |
| Net change in cash | -$-37.13M | $22.9M | $39.3M | -$-353.65M | -$-123.96M |
| Cash at end of period | $89.1M | $126.3M | $102.9M | $64M | $417.6M |
| Operating cash flow | -$-138.51M | -$-20.44M | -$-174.88M | -$-241.12M | -$-37.43M |
| Capital expenditure | $0.00 | $0.00 | -$-290K | -$-2.04M | -$-1.29M |
| Free cash flow | -$-138.51M | -$-20.44M | -$-175.17M | -$-243.16M | -$-38.72M |
Line items
Line items
Line items
About Coherus Oncology, Inc.
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
- CEO
- Dennis Lanfear
- Employees
- 145
- Beta
- 0.98
Explore
Frequently asked questions
What is the intrinsic value of Coherus Oncology, Inc. (CHRS)?
InvestorsCraft does not currently publish an intrinsic value for CHRS. How the IC value is calculated.
Is CHRS undervalued?
InvestorsCraft does not publish an undervaluation signal for CHRS at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.